Roman Windisch, Vladimir Kozousek. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Angiogenesis Inhibitors/therapeutic useAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedBevacizumabCombined Modality TherapyHumansInjectionsLaser CoagulationMaleMiddle AgedPhotochemotherapyPhotosensitizing Agents/therapeutic usePorphyrins/therapeutic useRetinal Diseases/diagnosisRetinal Diseases/drug therapyRetinal Diseases/surgeryRetinal Diseases/therapyRetinal VesselsTelangiectasis/diagnosisTelangiectasis/drug therapyTelangiectasis/surgeryTelangiectasis/therapyTomography, Optical CoherenceVascular Endothelial Growth Factor A/antagonists & inhibitorsVerteporfinVisual AcuityVitreous Body
Substances: See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedPhotosensitizing AgentsPorphyrinsVascular Endothelial Growth Factor AVerteporfinBevacizumab
Year: 2008 PMID: 18711474 DOI: 10.3129/i08-069
Source DB: PubMed Journal: Can J Ophthalmol ISSN: 0008-4182 Impact factor: 1.882